Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORATOS trial of Trixeo Aerosphere versus placebo on cardiac and lung function in COPD with hyperinflation
2025-521987-37-00Phase 4Authorised
- Sponsor
- AstraZeneca
- Start
- Nov 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 4, randomised, double-blind trial of budesonide in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by AstraZeneca. Primary endpoint: Change from baseline in left ventricular end diastolic volume index. Planned start Nov 2025; status: authorised.
02
Drugs
budesonide
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2025-521987-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521987-37-00.